Theravance, Inc. (NASDAQ:THRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.

Recs

0
Player Avatar jsgant13 (97.73) Submitted: 9/13/2010 1:06:44 PM : Outperform Start Price: $15.11 THRX Score: +28.16

Klarman

Featured Broker Partners


Advertisement